Partner David Rosen was quoted in a Modern Healthcare article, “Stakeholders anxious about FDA losing momentum after Gottlieb exits,” about the legacy of Food and Drug Administration Commissioner Dr. Scott Gottlieb, who announced his resignation last week.
Rosen said Gottlieb did a great job improving the generic-drug review and approval process, but that more needs to be done to address branded drugs that have no competition. “I still think the barrier to entry for generics is pretty high,” he said, citing the often insurmountable costs. “Also, the whole issue about patent certification is still subject to a fair amount of debate and clarification.”
Rosen said Gottlieb did a great job improving the generic-drug review and approval process, but that more needs to be done to address branded drugs that have no competition. “I still think the barrier to entry for generics is pretty high,” he said, citing the often insurmountable costs. “Also, the whole issue about patent certification is still subject to a fair amount of debate and clarification.”
People
Related News
03 May 2024
In the News
Jeff Symons’ Move to Foley Featured in Press
Foley & Lardner LLP partner Jeff Symons is featured in legal press for his recent arrival to the firm
03 May 2024
In the News
Nathaniel Lacktman on Healthleaders Podcast– ‘We’re seeing maturity in the telemedicine market’
Foley & Lardner LLP partner Nathaniel Lacktman discussed the upcoming American Telemedicine Association’s annual conference, new developments in telemedicine and digital health, the regulatory context, and the prospects for the industry’s future
02 May 2024
In the News
Jennifer Hennessy on American Privacy Rights Act – ‘This law does have teeth’
Foley & Lardner LLP partner Jennifer Hennessy assesses the prospects of what could be the first federal data privacy law passed in the United States